{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-003280","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.263511+00:00","generated_at":"2026-05-28T06:20:27.746486+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"EyePoint appoints Dr. Reginald Sanders, retina specialist and former ASRS president, to board","bullets":["Board expanded to nine members; Dr. Sanders appointed effective Jan 8, 2025.","Receives $45,000 annual cash retainer and option for 80,000 shares vesting over 3 years.","Sanders brings expertise as ex-president of American Society of Retina Specialists and PI for Lucentis.","He served as president and managing partner of Retina Group of Washington, largest U.S. retina practice.","Appointment coincides with Phase 3 trials for wet AMD and positive interim Phase 2 DME data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-003280","json":"https://secwatch.observer/filing/0000950170-25-003280.json","markdown":"https://secwatch.observer/filing/0000950170-25-003280.md","text":"https://secwatch.observer/filing/0000950170-25-003280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025003280/0000950170-25-003280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025003280/eypt-20250108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:20:27.746486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90646969be","claim":"Dr. Reginald Sanders was appointed as Director at EyePoint, Inc..","evidence_excerpt":"appointed Dr. Reginald Sanders, M.D. to fill the vacancy on the Board, effective January 8, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025003280/0000950170-25-003280-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}